Table 5. Multivariate Analyses of Factors Associated with RRT Trigger of Active SCM and Unplanned Readmission within 30 Days after Discharge.
| Factor | Univariate | p value | Multivariate | p value | |||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | aOR | 95% CI | ||||||
| RRT trigger of active SCM | |||||||||
| Age | 1.00 | 0.97–1.02 | 0.695 | 0.99 | 0.97–1.02 | 0.603 | |||
| Sex | |||||||||
| Female | 1.00 | ||||||||
| Male | 0.85 | 0.39–1.87 | 0.691 | 0.84 | 0.37–1.90 | 0.668 | |||
| Co-morbidities | |||||||||
| None | 1.00 | ||||||||
| Diabetes mellitus | 1.28 | 0.59–2.81 | 0.536 | ||||||
| Chronic liver disease | 0.00 | 0.998 | |||||||
| Chronic kidney disease | 1.85 | 0.61–5.58 | 0.274 | ||||||
| Congestive heart failure/prior MI | 1.85 | 0.73–4.71 | 0.198 | ||||||
| Cerebrovascular disease | 1.23 | 0.41–3.66 | 0.709 | ||||||
| Dementia | 0.74 | 0.10–5.70 | 0.774 | ||||||
| Chronic pulmonary disorder | 1.70 | 0.38–7.62 | 0.491 | ||||||
| Hematologic malignancy | 0.00 | >0.999 | |||||||
| Any solid malignancy | 0.58 | 0.27–1.25 | 0.162 | ||||||
| Connective tissue disorder | 2.40 | 0.29–20.20 | 0.419 | ||||||
| Charlson comorbidity score | 1.02 | 0.88–1.18 | 0.780 | 1.05 | 0.89–1.23 | 0.551 | |||
| Purpose of admission | 0.997 | ||||||||
| Operation | 1.00 | ||||||||
| URO procedures | 0.63 | 0.08–5.02 | 0.663 | ||||||
| URO cancer chemotherapy | 0.00 | 0.999 | |||||||
| URO cancer evaluation | 0.76 | 0.10–6.12 | 0.799 | ||||||
| Infection | 0.71 | 0.28–1.79 | 0.462 | ||||||
| Hematuria | 0.97 | 0.12–7.86 | 0.975 | ||||||
| Obstruction/voiding problem | 1.04 | 0.13–8.46 | 0.974 | ||||||
| Complicated conditions | 1.08 | 0.38–3.12 | 0.884 | ||||||
| SCM type | |||||||||
| Passive SCM | 1.00 | ||||||||
| Active SCM | 0.47 | 0.22–0.99 | 0.046 | 0.46 | 0.22–0.97 | 0.042 | |||
| Unplanned readmission within 30 days after discharge | |||||||||
| Age | 1.00 | 0.98–1.02 | 0.823 | 1.00 | 0.98–1.03 | 0.908 | |||
| Sex | |||||||||
| Female | 1.00 | ||||||||
| Male | 1.00 | 0.53–1.90 | 0.988 | 0.90 | 0.45–1.79 | 0.762 | |||
| Co-morbidities | |||||||||
| None | 1.00 | ||||||||
| Diabetes mellitus | 1.21 | 0.65–2.27 | 0.551 | ||||||
| Chronic liver disease | 1.96 | 0.55–7.01 | 0.302 | ||||||
| Chronic kidney disease | 0.45 | 0.11–1.93 | 0.285 | ||||||
| Congestive heart failure/prior MI | 0.96 | 0.39–2.35 | 0.931 | ||||||
| Cerebrovascular disease | 0.87 | 0.33–2.28 | 0.771 | ||||||
| Dementia | 2.09 | 0.68–6.40 | 0.198 | ||||||
| Chronic pulmonary disorder | 0.95 | 0.22–4.18 | 0.994 | ||||||
| Hematologic malignancy | 0.00 | >0.999 | |||||||
| Any solid malignancy | 1.43 | 0.69–2.94 | 0.333 | ||||||
| Connective tissue disorder | 1.36 | 0.16–11.32 | 0.773 | ||||||
| Charlson comorbidity score | 1.05 | 0.93–1.18 | 0.428 | 1.02 | 0.88–1.18 | 0.788 | |||
| Purpose of admission | 0.459 | 0.491 | |||||||
| Operation | 1.00 | 1.00 | |||||||
| URO procedures | 0.51 | 0.07–4.02 | 0.524 | 0.51 | 0.06–4.05 | 0.524 | |||
| URO cancer chemotherapy | 5.04 | 1.19–21.29 | 0.028 | 5.53 | 1.19–25.58 | 0.029 | |||
| URO cancer evaluation | 1.31 | 0.28–6.11 | 0.734 | 1.32 | 0.27–6.54 | 0.735 | |||
| Infection | 1.30 | 0.63–2.69 | 0.483 | 1.31 | 0.63–2.73 | 0.469 | |||
| Hematuria | 0.78 | 0.10–6.30 | 0.819 | 0.83 | 0.10–7.02 | 0.867 | |||
| Obstruction/voiding problem | 1.81 | 0.38–8.69 | 0.459 | 1.87 | 0.38–9.11 | 0.438 | |||
| Complicated conditions | 1.68 | 0.71–3.96 | 0.235 | 1.62 | 0.65–4.06 | 0.305 | |||
| SCM type | |||||||||
| Passive SCM | 1.00 | ||||||||
| Active SCM | 0.61 | 0.34–1.10 | 0.098 | 0.58 | 0.32–1.06 | 0.076 | |||
CI, confidence interval; MI, myocardial infarction; OR, odds ratio; RRT, rapid response team; SCM, surgical co-management; URO, urology.